Mergers and acquisitions (M&As) are an important but unstudied aspect of nanotechnology's evolution. This paper uses case review and bibliometric analysis to examine 20 M&As involving acquired firms in the nanotechnology domain. The guiding proposition is acquired firms provide complementarities to the acquiring firms. Key measures given consideration include the nature of the post-acquisition organization, whether the pre-acquisition geographic location is retained, the purpose of the acquisitions as indicated in news releases, and the extent of similarity in research publications and patents. Differences by the country of the acquiring firm and subindustry are noted. Within the limitations of the case study approach, the results suggest that acquired firms in the nanotechnology domain to provide complementary capabilities to their acquirers.
Introduction
Nanotechnology has evolved in the more than 20 years since the emergence of substantial research and commercialization activity. How the field changes and accommodates innovations is important to understanding its emergence and anticipating future development. This paper uses case review and bibiometric analysis in investigating the role of mergers & acquisitions (M&A) in the nanotechnology domain.
M&As have been widely investigated, but commonly in the context of other technologyintensive, albeit traditional sectors (see for example, Bower 2001, Villalonga and McGahan 2005) . While these studies are insightful, they generally do not address the case of an emerging technology-except for studies of biotechnology-or do not consider the peculiar features of a general-purpose technology such as nanotechnology ).
In nanotechnology, companies, rather than universities or government laboratories, have the fastest rate of publishing and patenting. More than 17,800 unique companies had a nanotechnology publication or patent between 1990 and 2009 based on a definition of nanotechnology detailed in Porter et al. (2008) . Large companies were involved in 60% of all patents, but the share of patents from small and medium-sized enterprises (SMEs) grew from fewer than 30% in 1990 to more than 50% in 2009. Nanotechnology patents were largely comprised of nanomaterials and nanoelectronics patents, with nanobiotechnology accounting for about one in nine of these documents but growing at a faster rate than the other two subdomains.
Using case reviews and bibliometric analysis of 20 M&As that involved SMEs in the nanotechnology domain from 1990 to 2009, this paper seeks to advance insights into the innovative contribution of smaller firms to their larger firm counterparts.
SMEs and M&A in the context of the broader dynamics of an emerging field
Nanotechnology studies have focused on scientific publications and patents, with a heavy emphasis given to university research. Fewer works have sought to understand dynamics by looking at the enterprise level. One exception is Mangematin et al. (2011) in their examination of the subsidiaries of the top 1,400 global companies in the 2008 R&D Scoreboard. The authors reported that 4% of these global companies' subsidiaries are focused on nanotechnology, accounting for one-third of all patents from 1998-2008. These subsidiaries were found to be engaged in general purpose activities rather than in specialized scientific concentrations.
Given the rapid growth of SMEs in nanotechnology patenting and publishing, it is especially useful to examine the business trajectories of these firms (Fernández-Ribas 2009) .
SMEs involved in nanotechnology may remain independent and grow, some will go out of business, and others will be acquired. Firm acquisition has been found to be important in the evolution of other emerging technologies such as biotechnology, particularly when the acquired firms contribute "complementary assets"-those needed to support marketing and commercialization of new technologies-to the acquiring firm (Arora and Gambardella 1990 , 1995 , Teece 1986 , Rothaermel 2001 ). This paper focuses on the role of M&A in nanotechnology's commercial emergence.
Lessons can be drawn from research on science-based entrepreneurial firms (SBEFs) which engage in the transfer of research findings into commercial domains. Many SBEFs are spinoffs of universities or government or private non-profit laboratories. SBEFs are distinct from other types of SMEs in that the former typically experience longer lag times between research findings and commercial payoffs. Early stage funding can be more difficult to obtain and risk levels associated with highly inventive research and development (R&D) may be greater (Colombo et al 2010) .
Studies in mature technology-intensive industries, and in science-intensive emerging fields such as biotechnology, have shown that M&A deals are connected with diverse corporate strategies, with particular attention given to the value of the acquired capabilities. Larger corporations engage in M&As to gain new competencies through R&D, but also to obtain entry into a new market, to extend a product line, to reduce overcapacity, or for other factors that address certain strategic business objectives (Bower 2001) . M&As have become a preferred method to gain new competencies, particularly when technology-based firms are involved. Villalonga and McGahan (2005) found in an analysis of 9,276 acquisitions, divestitures and alliances from 1990 to 2000, that acquisitions were preferred over other methods when the target had substantial technological resources.
SBEFs in particular are more likely than other types of entrepreneurial firms to become the M&A targets. Bonardo et al (2010) examined the propensity of SBEFs to be involved in M&As compared to other high technology firms. The authors' analysis of 499 firms in five high technology sectors that underwent initial public offerings (IPOs) in three European countries found that SBEFs had lower profitability (i.e., negative return on assets), higher patenting rates, and higher likelihood of M&A than the comparison group of other firms engaged in IPOs.
Likewise, Carayannopoulos and Auster (2010) work on 209 biotechnology firm M&As and alliances from [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] showed that M&As were more likely when the biotechnology subfield was more complex (as measured by diversity of patent classes) and exhibited greater knowledge value (as measured by sales growth of the biotechnology subfield) than when it was more specific (as measured by R&D intensity).
What happens when the SBEF is acquired? Research findings have been mixed. Many of these studies used large scale datasets involving secondary data such as patents and R&D expenditures. These studies, from economics and management literatures, typically have found that patenting and R&D efficiency decline following M&As (e. g., Hitt, 1991) . Recent and smaller sample firm-level studies have yielded more consistent and positive results. Cloodt et al. (2006) found that the M&A deals of 347 firms led to decreasing innovative performance (i.e. patenting) when the acquired and acquiring firms' knowledge bases were too similar or too unrelated. Cassiman et al (2005) interviewed R&D managers across 31 M&As involving 62 companies in a range of industries in the 1990s and early 2000s; they found that complementary technologies had a positive effect, especially where the firms were direct competitors. Makri et al (2010) examined 96 M&As in 1996 in the electronics, chemicals, and pharmaceuticals industry, using publications and patents to assess outcomes; the authors found that post-merger patenting was higher three to five years after M&As involving firms with complementary technologies. Miozzo et al (2011) used interviews with select UK biotechnology company informants, finding that M&As with complementary capabilities and technology were more likely to be retained in the host country than those with similar characteristics.
The distinctive characteristics of the nanotechnology field can arguably provide a further perspective on the M&A phenomenon. Nanotechnology has been considered a general purpose technology with pervasive effects on a wide range of industry sectors. This finding raises questions about the role of M&A and the strategies of the acquiring firms, suggesting that firms may acquire others in the field of nanotechnology not only to, for example, source complementary assets, have access to intellectual property or enter new markets, but also to gain expertise in strategic positioning in a very uncertain emerging field. Although nanotechnology has been associated with the generation of hundreds of thousands of publications and patents, the field remains at an early phase of commercialization, at least within the time horizon considered, due to reasons such as high uncertainty about the definition and size of markets and the best business models to address them (Parandian and Te Kulve 2012 , Shapira and Youtie 2012 . Within these limitations, this work posits that nanotechnology M&As offer complementary capabilities to acquiring firms. These complementarities may be evidenced by organizational arrangements (e.g., whether the acquired firm may be absorbed or remain as an independent unit), technological or product arrangements, publication and patent portfolios, and/or which anticipates individual, long-term strategies of the firm (e.g. whether the acquired firm seeks to further develop the acquired technologies.) It is posited that acquired firms provide an "augmented" set of complementary assets that includes not only assets to help marketing and commercialization but also valuable know-how concerning business strategies that may or may not work in the deployment of the new technologies in this emerging field.
Methods and data
The starting point of this research was the creation of a randomly selected sample of 125 non- inventors/assignees, were extracted. Of the 17,800 corporate organizations extracted, some 6,000
were based in the USA. A random selection process was then applied to these USA-based
companies to obtain a sample of 125 active nanotechnology SMEs in the USA that were independently owned and operated . After setting a threshold of USA-based corporate entities with at least four publications or patents, we had to select 193 firms (under a random-sampling with replacement design), because 68 of the initially selected firms were found to be either acquired by or subsidiaries of large corporations or out of business. Of these 68 firms, 20 were explicit targets of M&As.
This paper focuses on the 20 acquired firms found in this subset and uses bibliometric analyses and other secondary methods to investigate them in case reviews. Whether this subset of acquired SMEs is statistically representative of the SMEs or M&A deals in the population is not necessarily a concern (even though the 20 SMEs resulted from a random sampling selection process) because this paper seeks to characterize whether there is a potentially distinctive role of M&A in the emergence of nanotechnology and not to estimate the characteristics of the whole population.
For each of the 20 firms, the researchers obtained the name, headquarters location, year of founding, and key products. Also gathered for the acquiring firm were name, headquarters location, and key products. Acquisition attributes collected included the size and nature of the acquisition, as well as the structural form resulting from the acquisition. This information was obtained from company websites, news releases announcing the acquisition, and corporate databases such as Dun & Bradstreet and Reference USA. News releases were also examined to understand the extent to which the acquisition involves complementary or similar technologies and products. The examination focuses on both a set of terms such as "complement,"
"accelerate," "enhance," "unique," "broaden," "extend," and "savings" as indicators of technology enhancements potentially brought by the acquired nanotechnology (noting that many news releases have a positive tenor in their description of the acquisition).
In addition, bibliometric analyses of publication and granted patent information for the acquiring and acquired firm were performed to enable an assessment of similarities and complementarities of acquired and acquiring firms. Studies of M&A have used these types of measures of complementarity (Makri et al 2010) . In the case of scientific publications, we use the journal subject category designation, where a journal subject category is the designation that the Web of Science gives to a publication based on cross-citation similarities. Our measure reflects the extent to which the acquiring company has the same journal subject category/categories as the most prevalent category/categories in acquired company publications until the year before the acquisition. If there is not a common category, then multiple categories are taken together. The ratio of the number in the most common category/categories divided by the total number of publications prior to the year before the acquisition, which ranges from 0 (no categories in common) to one (highly similar), is presented as a proxy of similarity or complementarity of the two firms. A similar approach is used for granted patents, focusing on three-digit USPTO patent classes. These ratios are represented as scientific similarity and technological similarity in the measures below (where ad represents the acquired firm and ac 
Results
The 20 acquired US-based SMEs engaged in nanotechnology publishing and/or patenting operate across a range of industries ( The similarity or complementarity of the business areas of acquired and acquiring firms provides a more developed picture of these M&As. The broad business areas of the acquiring and acquired firms are surprisingly not that similar. Matrix Semiconductor's main products concerned integrated circuits whereas SanDisk is known as a provider of electronic storage.
Although Life Technologies (formerly Invitrogen) focuses on biomedical equipment, kits, assays, and bioinformatics, Molecular Probes (one of its acquisitions) produced fluorescencebased detection products and solutions for biomedical and other industries while Visigen
Biotechnologies was involved with whole gene sequencing.
News releases from the acquiring firm were available for 19 of the 20 acquisitions and the parts pertaining to the contributions of the acquired firm are excerpted (Table 3) . Only one of the news releases (Semiconductor Technologies Inc.'s acquisition of Conductus Inc.) indicated that the acquisition was of a similar company and designed to achieve cost savings. The other releases mentioned a distinctive technology or product gained through the acquisition. Four of the releases used the term "enhance" to describe the distinctive contribution of the acquired firm.
Three used the terms "broaden" or "extend" to suggest how the acquisition will enlarge or expand the acquiring firm's offerings. One explicitly mentioned that the acquisition "would complement our focused product and market strategies very well" while another referenced the results of the acquisition in terms of "helping us develop a "unique portfolio of products."
Although news releases tend to have a positive tone (which may overemphasize the benefits of the M&A), these findings nevertheless serve as an indication of the type of complementary contributions offered by acquired firms in the nanotechnology domain.
[
INSERT TABLE 3 NEAR HERE]
Bibliometric examination of complementarities in the nanotechnology M&A cases is performed through an analysis of scientific (publication) and technological (granted patent) similarity scores. As previously indicated, these scores are based on ratios indicating the extent to which the acquiring firm has publications or patents in the acquired firm's most prevalent journal subject category or patent class prior to the year before the acquisition. No publication and patent data were available for ImaRx Therapeutics, Inc., Callida Genomics, Inc., Triton Biosystems Inc., and Systran Corp. under this timing restriction. The scientific ratio sums the number of publications in the most prevalent journal subject category/categories common to acquired and acquiring firm, divided by the total number of publications for these firms; the technological ratio does the same for the most prevalent patent technology class/classes.
Scientific similarity ratios ranged from 0 (for the Indium Corp. acquisition of Reactive Nanotechnologies, Inc.) to 1.0 (for the SanDisk Corp. acquisition of Matrix Semiconductor).
Electronics firms had greater similarity in their publication emphases than did life science firms;
four of the six firms with ratios above 0.50 were in the electronics area while only one was in life sciences. The technological similarity ratios range from 0 (for the Accelrys acquisition of Molecular Simulation, Inc.) to 0.7 (for the Apovia AG acquisition of Immune Complex Corporation). Less technological similarity than scientific similarity is observed in that only two of the cases had ratios above 0.50. Nanobiotechnology firms had higher technological similarity than those in the other nanotechnology domains. Only one of the 20 case M&As had both scientific and technological similarity scores above 0.50, suggesting that nearly all of these cases had some degree of complementarity from a bibliometric standpoint.
INSERT TABLE 4 NEAR HERE]
Finally, the four acquisitions by firms outside the USA resulted in the acquired firm's becoming subsidiaries with identifiable appellations. The operations of these four firms remained at their current locations. USA-based acquirers were more diverse in their geographic treatment of acquired firms. In the case of life science acquisitions, five of the six USA-based acquiring firms appeared to retain the acquired firm's separate location. Acquired firm absorption was more prevalent in the electronics industry, where only two of the six USA-based acquiring firms retained the acquired firm's separate location. In all, nine of the 20 acquisitions resulted in the acquired firm being retained as a separate business unit, and 14 of the 20 operate in their preacquisition business location.
Conclusions
This paper addresses the gap in understanding of the contribution of M&As in the emerging nanotechnology domain by using bibliometric analysis, website information, news releases, and business databases, to examine 20 case M&A examples. These case examples resulted from a process to select a sample of companies at random from large scale datasets of nanotechnologyrelated publications and patents aggregated to the organizational level.
The methodology used in this paper is subject to certain limitations. The focus on 20
M&As in the nanotechnology domain means that the results are more descriptive than generalizable. In addition, the post-acquisition profitability or R&D performance of the acquiring firm is not gauged. Given that these 20 acquisitions, with the exception of one, are relatively modest in size, linking performance to the acquisition is fraught with difficulties, albeit many factors can explain why these nanotechnology-related acquisitions tend to be moderate in size, including factors related to market uncertainty associated with nanotechnology rather than company features per se. Moreover, many of these firms are not solely involved in nanotechnology, although they have a good number of publications and/or patents in the domain;
for example, only 7% of the 189 total publications with authors from Millenium Pharmaceuticals were in the nanotechnology domain while nearly three-quarters of the 130 publications associated with Digital Instruments were in the nanotechnology domain. Future research may draw on larger samples and statistical analysis to probe relationships between the categories investigated by this paper. However, firm classifications in terms of delineating nanotechnology boundaries will have to be resolved in such a scale-up effort.
The distance of the acquiring firm is a factor in that all the non-US acquiring firms retain their acquisitions as separate subsidiaries or divisions. Underlying this finding may be the value independence can bring versus being absorbed as another resource to the company. Industry differences are apparent in this analysis. SMEs in electronics and ICT are less likely to appear post-acquisition as standalone units, and are more apt to have similar publication profiles (albeit less similar patent profiles), than life sciences firms. The nature of electronics and ICT may militate against retaining geographically separate facilities as R&D in these industries tends to require greater integration (Leitner et al, 2011) . Likewise Non-USA and life sciences acquiring firms tend to see more of a distinctive value from the acquired firm than USA-based, electronics firms, notwithstanding the small number of cases in this analysis, and are more apt to retain the acquired firm's location.
The large proportion of acquired SMEs established before the 1990s suggests that these older firms work in industries for which nanotechnology is an enabling feature of an existing, product or service or, in the case of the instruments firms, a new subsector for measurement and characterization. The lack of specialized nanomaterials firms in this set of acquired SMEs also supports the idea of acquisitions of firms that have either applied nanotechnology to a concrete product already (i.e. the case of most of these firms) or have some kind of expertise to deal with nanotechnology enhancement. News releases about the M&A, which are admittedly positive, further suggest that only one of the 20 acquisitions involved cost savings associated with absorbing a competitor, whereas the remainder indicate distinctive innovation benefits to the acquiring firm from the acquisition.
There are a range of factors that can explain how an emerging field such as nanotechnology evolves. M&As are part of the explanation of how innovation occurs in the field.
In some cases, particularly in nanoelectronics, this union leads to absorption of assets and resources, while in others, particularly nanobiotechnology, it results in maintaining the assets and resources as separate units. Whether these positions will continue remains to be determined. Oncologic, Inc, renamed Aduro BioTech "We believe the NTTM (direct infusion) method is the shortest path to the clinic, and we hope to start a clinical trial for accessible head and neck cancer in 2009…Our basic strategy is to be first to show direct clinical benefit with 'thermal therapy' in humans, then to move on the more interesting systemic approach with the TNTTM method, which we believe holds promise for metastatic disease."
Geo-Centers, Inc SAIC "This acquisition gives us the opportunity to enhance the level of services and solutions we offer our customers in the area of homeland security and defense" K Systran Corp Infoscitex Corporation, now Curtiss-Wright Controls Inc.
"The acquisition of Systran significantly improves Curtiss-Wright's position in the rugged commercial-off-the-shelf (COTS) embedded systems marketplace by adding valuable data communications capabilities to our existing embedded systems product offering…In addition to expanding our technology offerings within the aerospace and defense markets, Systran broadens our market reach into medical imaging and industrial automation applications, giving us the ability to cross-sell existing products into these markets." E / T Note: 1. Acquisitions classified as they relate to: T=technology, E=market-entry, K=knowledge, expertise, IP=intellectual property, A=other assets (e.g. sales, marketing) Source: acquiring company websites and author analysis. 
